Literature DB >> 29550809

Presenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours.

Ron Basuroy1, Cathy Bouvier2, John K Ramage3, Maia Sissons2, Alexandra Kent4, Raj Srirajaskanthan3,4.   

Abstract

The gastrointestinal tract and pancreas are common primary sites for neuroendocrine tumours (NETs). Patients often report a long duration of non-specific symptoms in the year prior to diagnosis. The aims of this study were, firstly, to establish pre-diagnosis patterns of symptoms, and secondly, to determine the time from onset of symptoms to NET diagnosis and understand the interaction with primary and secondary healthcare providers. A survey was designed on a web-based survey platform with the focus on patient symptoms prior to diagnosis and a screen for functional diarrhoea (Rome III criteria [C4]). A total of 303 responses were received. The median duration from the time of first symptoms to diagnosis was 36 months for small bowel NETs and 24 months for pancreatic NETs. Common first symptoms were pain (36%), flushing (24%), and diarrhoea (24%); 29% of small bowel NET respondents were given an initial diagnosis of irritable bowel syndrome. Dyspepsia was the second most common initial incorrect diagnosis. Respondents saw their GP 5 times over a median 18-month period for their symptoms; 31% of patients were diagnosed following unplanned emergency admission. In conclusion, this survey demonstrates a median time to diagnosis of 36 months for patients with small bowel NETs. Incorrect initial diagnosis appears to be very common, with a high number of attendances in primary and secondary care prior to a correct diagnosis being made. An earlier diagnosis may improve patients' quality of life and possible survival.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Gastrointestinal tract; Irritable bowel syndrome; Neuroendocrine tumour; Pancreas; Rome criteria; Symptoms

Mesh:

Year:  2018        PMID: 29550809     DOI: 10.1159/000488510

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  6 in total

1.  Neuroendocrine tumours: what gastroenterologists need to know.

Authors:  Mohid S Khan; D Mark Pritchard
Journal:  Frontline Gastroenterol       Date:  2020-09-22

2.  LncRNA SNHG15: A new budding star in human cancers.

Authors:  You Shuai; Zhonghua Ma; Jianwei Lu; Jifeng Feng
Journal:  Cell Prolif       Date:  2019-11-27       Impact factor: 6.831

3.  Neuroendocrine tumors in Panama: A nationwide database analysis.

Authors:  Moises Cukier; Ruth Vergara; Jorge D Mendez-Rios; Omar Castillo; Irma Barrera; Eliecer Tello; Olivia El Achtar; Yong Loo; Hector Tapia; Guadalupe Perez; Maximino Peña
Journal:  Mol Clin Oncol       Date:  2021-06-11

4.  Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.

Authors:  Anja Rinke; Christoph Maintz; Lothar Müller; Matthias M Weber; Harald Lahner; Marianne Pavel; Wolfgang Saeger; Aude Houchard; Hanna Ungewiss; Stephan Petersenn
Journal:  Exp Clin Endocrinol Diabetes       Date:  2021-07-22       Impact factor: 2.949

5.  Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.

Authors:  Mohid S Khan; Thomas Walter; Amy Buchanan-Hughes; Emma Worthington; Lucie Keeber; Marion Feuilly; Enrique Grande
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

6.  Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet).

Authors:  F Panzuto; M Maccauro; D Campana; A Faggiano; S Massironi; S Pusceddu; F Spada; D Ferone; R Modica; C M Grana; P Ferolla; M Rinzivillo; G Badalamenti; M C Zatelli; F Gelsomino; E De Carlo; M Bartolomei; M P Brizzi; S Cingarlini; A Versari; G Fanciulli; E Arvat; E Merola; M Cives; S Tafuto; S Baldari; M Falconi
Journal:  J Endocrinol Invest       Date:  2020-08-16       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.